Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- GARDP, Indian Firm Ink Deal to Expand Access to Shionogi Antibiotic
September 13, 2023
- Eisai Sets Up Digital Biz Unit to Build Dementia Ecosystem
September 13, 2023
- Takeda Shoots for 80% Cut in Paper Materials, Switch to All-EV/HV Fleet by FY2025
September 12, 2023
- Daiichi Sankyo’s HER3 ADC Posts Positive PII Data in 3rd Line NSCLC, US Filing Eyed by March
September 12, 2023
- EA Pharma, China’s TransThera Hook Up on GI Drug Research
September 12, 2023
- GSK Files Myelofibrosis Drug Momelotinib in Japan
September 12, 2023
- China’s Haihe Makes Japan Debut with NDA Filing of Lung Cancer Drug
September 12, 2023
- Sumitomo to Ramp Up Regenerative, Cell Therapy Biz to Counter Latuda Patent Cliff
September 11, 2023
- Otsuka, Shape Link Up on AAV Gene Therapies for Eye Diseases
September 11, 2023
- TA-MUC1-Directed ADC Enters Clinic for Solid Tumors: Daiichi Sankyo
September 11, 2023
- Japan Ethical Drug Sales Up 7.9% in July: Crecon
September 11, 2023
- After Idorsia Deal, Sosei Pivoting to High-Profit Model with In-House Sales System
September 8, 2023
- Astellas Drops IRA Lawsuit after Xtandi Avoids 1st Drug List
September 8, 2023
- Daiichi Sankyo Files XBB.1.5 COVID Jab, Eyes Japan Rollout by Year-End
September 8, 2023
- Maruho Gets Asia Rights to Hyperhidrosis Wipe Drug
September 8, 2023
- Keytuda Filed in Japan in NSCLC Neoadjuvant/Adjuvant Setting: MSD
September 8, 2023
- Brexpiprazole Combo Logs Mixed Results in 2 PTSD Trials: Otsuka/Lundbeck
September 8, 2023
- Noile-Immune Hits Early Milestone for CAR-T Tech Transfer to Chugai
September 7, 2023
- PNH Drug Crovalimab Accepted for FDA Review: Chugai
September 7, 2023
- Daiichi Sankyo’s Omicron-Tailored Booster Hits Main Goal: Japan PIII
September 7, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…